7 assets in Astrocytoma, IDH-Mutant, Grade 3

Therapeutic assets addressing Astrocytoma, IDH-Mutant, Grade 3, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Safusidenib Astrocytoma, IDH-Mutant, Grade 3	Nuvation Bio Inc.	P3	B (60)
Vorasidenib Astrocytoma, IDH-Mutant, Grade 3	Alliance for Clinical Trials in Oncology	P3	B (60)
Eflornithine Astrocytoma, IDH-Mutant, Grade 3	Mayo Clinic	P1/2	CCC (48)
Retifanlimab Astrocytoma, IDH-Mutant, Grade 3	Mayo Clinic	P1/2	CCC (48)
Fludeoxyglucose Astrocytoma, IDH-Mutant, Grade 3	City of Hope Medical Center	P1	CC (43)
Telaglenastat Astrocytoma, IDH-Mutant, Grade 3	National Cancer Institute (NCI)	P1	CC (43)
Triapine Astrocytoma, IDH-Mutant, Grade 3	National Cancer Institute (NCI)	P1	CC (43)